Genomics and Population Health Action Collaborative
Evidence (November 2015-February 2017)
|Ned Calonge, M.D.
President and CEO
The Colorado Trust
Leader, Evidence Working Group
The goal of the Evidence Working Group was to understand the type and level of evidence required to implement genomic applications at the public health level. This work focused primarily on two case studies – mutations in BRCA1/2 that cause hereditary breast and ovarian cancer and mutations that cause Lynch syndrome. This working group also examined current gaps in the evidence that exist for supporting a Tier 1 genomic application at the population level. Group participants explored ways to estimate the public health impact of a genomics program, and discussed how these approaches can potentially drive the decision to implement.
Working Group Products
Members of the Evidence Working Group prepared the following white paper, which details the process of horizon scanning and how evidence assessment consortia evaluated genetic tests for BRCA1/2 and Lynch syndrome. The paper includes perspectives on using evidence assessment as a tool to support the integration of these applications within public health.
For more information about the Genomics and Population Health Action Collaborative, please click here.